Glaucoma agents: Difference between revisions

From Doc Moates Wiki
Jump to navigation Jump to search
NCLEX nursing pharmacology monographs — batch import
 
Add medication infobox (Drugbox) to monographs
 
Line 1: Line 1:
{{Drugbox
| name = Glaucoma agents
| therapeutic = Antiglaucoma
| pharmacologic = Prostaglandin analog, ophthalmic beta blocker, alpha-2 agonist, carbonic anhydrase inhibitor, cholinergic
| onset = Latanoprost once daily at night; others one to three times daily.
| halflife = Local; no routine level.
| routes = Ophthalmic
| highalert = No
| blackbox = None
| antidote = Supportive care.
| pregnancy = Use only if clearly needed.
}}
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''

Latest revision as of 16:09, 17 June 2026

Glaucoma agents
Drug monograph · NCLEX study reference
Therapeutic classAntiglaucoma
Pharmacologic classProstaglandin analog, ophthalmic beta blocker, alpha-2 agonist, carbonic anhydrase inhibitor, cholinergic
Onset / peak / durationLatanoprost once daily at night; others one to three times daily.
Half-life / levelLocal; no routine level.
RoutesOphthalmic
High-alert (ISMP)No
Black box warningNone
Antidote / reversalSupportive care.
Pregnancy / lactationUse only if clearly needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Glaucoma agents — Antiglaucoma; Prostaglandin analog, ophthalmic beta blocker, alpha-2 agonist, carbonic anhydrase inhibitor, cholinergic.

Identification

  • Therapeutic class: Antiglaucoma.
  • Pharmacologic class: Prostaglandin analog, ophthalmic beta blocker, alpha-2 agonist, carbonic anhydrase inhibitor, cholinergic.

Pharmacology

  • Mechanism of action: Lower intraocular pressure by increasing aqueous outflow (latanoprost, pilocarpine) or decreasing aqueous production (timolol, brimonidine, dorzolamide).
  • Onset / peak / duration: Latanoprost once daily at night; others one to three times daily.
  • Half-life / therapeutic level: Local; no routine level.

Clinical use

  • Indications: Open-angle glaucoma and ocular hypertension.
  • Usual dose, route, frequency: One drop per affected eye, frequency by agent.
  • Maximum dose / adjustments: Space different drops by at least 5 minutes.

Safety

  • Contraindications: Timolol with asthma, COPD, bradycardia, or heart block (systemic absorption).
  • Black box warning: None.
  • Interactions: Systemically absorbed timolol adds to oral beta blockers; dorzolamide is a sulfonamide.
  • Pregnancy / lactation: Use only if clearly needed.
  • High-alert: No.

Adverse effects

  • Common side effects: Eye stinging and redness; latanoprost darkens the iris and lengthens and darkens eyelashes; pilocarpine causes miosis and dim vision.
  • Serious effects to report: Timolol systemic effects (bradycardia, bronchospasm), severe eye pain or vision change.
  • Antidote / reversal: Supportive care.

Nursing process

  • Assessment before administration: Intraocular pressure, respiratory and cardiac history (timolol), eye appearance.
  • Interventions during therapy: Apply punctal occlusion (press the inner corner) for 1 minute to reduce systemic absorption; wait 5 minutes between different drops; do not touch the dropper to the eye.
  • Monitor: Intraocular pressure, heart rate and breathing (timolol), eye changes.
  • Evaluation / expected outcome: Lowered intraocular pressure.

Patient teaching

  • Patient teaching: Latanoprost may permanently darken eye color and lashes; press the inner corner after drops; do not touch the tip to the eye; never stop glaucoma drops abruptly.
  • Notify provider if: Eye pain, vision changes, slow heartbeat or wheezing (timolol).
  • Administration tips: Punctal occlusion; 5 minutes between drops; ointment last.